First-Line Durvalumab and Tremelimumab With Chemotherapy for RAS-Mutated Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Nat. Med. 2023 Aug 01;29(8)2087-2098, M Thibaudin, JD Fumet, B Chibaudel, J Bennouna, C Borg, J Martin-Babau, R Cohen, M Fonck, J Taieb, E Limagne, J Blanc, E Ballot, L Hampe, M Bon, S Daumoine, M Peroz, H Mananet, V Derangère, R Boidot, HA Michaud, C Laheurte, O Adotevi, A Bertaut, C Truntzer, F GhiringhelliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.